{"bill": {"#text": "\n  ", "form": {"current-chamber": {"#tail": "\n    ", "#text": "IN THE HOUSE OF REPRESENTATIVES"}, "#text": "\n", "congress": {"#tail": "\n    ", "#text": "113th CONGRESS"}, "#tail": "\n  ", "legis-num": {"#tail": "\n    ", "#text": "H. R. 3742"}, "official-title": {"#tail": "\n  ", "#text": "To provide for approval of certain drugs and biological products indicated for use in a limited population of patients in order to address increases in bacterial and fungal resistance to drugs and biological products, and for other purposes."}, "session": {"#tail": "\n    ", "#text": "1st Session"}, "distribution-code": {"#tail": "\n    ", "@display": "yes", "#text": "I"}, "action": {"action-date": {"#tail": "\n      ", "@date": "20131212", "#text": "December 12, 2013"}, "#tail": "\n    ", "action-desc": {"#tail": "\n    ", "#text": "\n        ", "committee-name": {"#tail": "\n      ", "@committee-id": "HIF00", "#text": "Committee on Energy and Commerce"}, "sponsor": {"#tail": " (for himself, ", "#text": "Mr. Gingrey of Georgia", "@name-id": "G000550"}, "cosponsor": [{"#tail": ", ", "#text": "Mr. Gene Green of Texas", "@name-id": "G000410"}, {"#tail": ", ", "#text": "Mr. Shimkus", "@name-id": "S000364"}, {"#tail": ", ", "#text": "Ms. Eshoo", "@name-id": "E000215"}, {"#tail": ", ", "#text": "Mr. Whitfield", "@name-id": "W000413"}, {"#tail": ", ", "#text": "Ms. DeGette", "@name-id": "D000197"}, {"#tail": ", ", "#text": "Mrs. Blackburn", "@name-id": "B001243"}, {"#tail": ", ", "#text": "Mr. Engel", "@name-id": "E000179"}, {"#tail": ", and ", "#text": "Mr. Griffith of Virginia", "@name-id": "G000568"}, {"#tail": ") introduced the following bill; which was referred to the ", "#text": "Mr. Butterfield", "@name-id": "B001251"}]}, "#text": "\n      "}, "legis-type": {"#tail": "\n    ", "#text": "A BILL"}}, "@bill-stage": "Introduced-in-House", "@bill-type": "olc", "@dms-id": "HA96D6FA4F7714153AE34671499644575", "@public-private": "public", "legis-body": {"#tail": "\n", "@style": "OLC", "section": [{"@section-type": "section-one", "#tail": "\n    ", "text": {"#tail": "\n    ", "quote": {"short-title": {"#tail": "\n        ", "#text": "Antibiotic Development to Advance Patient Treatment Act of 2013"}, "#tail": ".", "#text": "\n          "}, "#text": "This Act may be cited as the ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "1."}, "header": {"#tail": "\n      ", "#text": "Short title"}, "#text": "\n      ", "@id": "H90C6D43D99F041C39AC6EBD9172ED895"}, {"#tail": "\n    ", "enum": {"#tail": "\n      ", "#text": "2."}, "header": {"#tail": "\n      ", "#text": "Approval of certain drugs for use in a limited population of patients"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n        ", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by adding at the end the following:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 505 of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "21 U.S.C. 355", "@value": "usc/21/355"}, "@parsable-cite": "usc/21/355", "#text": "\n            ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "Approval of certain antibacterial and antifungal drugs"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n        ", "#text": "."}, "#tail": "\n      ", "subsection": {"#tail": "\n          ", "enum": {"#tail": "\n            ", "#text": "(x)"}, "header": {"#tail": "\n            ", "#text": "Approval of certain antibacterial and antifungal drugs for use in a limited population of patients"}, "paragraph": [{"#tail": "\n            ", "@id": "HDE48B45E50664C2EA3693A3DB3CF488D", "enum": {"#tail": "\n              ", "#text": "(1)"}, "header": {"#tail": "\n              ", "#text": "Approval"}, "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "At the request of the sponsor of an antibacterial or antifungal drug that is intended to treat a serious or life-threatening disease or condition, the ", "@display-inline": "yes-display-inline"}, "#text": "\n              ", "subparagraph": [{"#tail": "\n              ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " to treat a limited population of patients for which there is an unmet medical need;", "@entity-type": "act", "#text": "subsection (c)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:c"}, "#text": "may approve the drug under "}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "#text": "\n                ", "@id": "H0B3D2493F1824D5D8BEE52181ADBD64E", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " deems necessary; and", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "in determining whether to grant such approval for a limited population of patients, may rely on traditional endpoints, alternative endpoints, or a combination of traditional and alternative endpoints; datasets of limited size; pharmacologic or pathophysiologic data; data from phase 2 clinical studies; and such other confirmatory evidence as the "}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "#text": "\n                ", "@id": "H7071094BE5E4492F9E36D2D3B89190F9", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n              ", "quote": {"#tail": ".", "#text": "This drug is indicated for use in a limited and specific population of patients."}, "#text": "shall require the labeling of drugs approved pursuant to this subsection to prominently include in the prescribing information required by ", "external-xref": {"#tail": " of title 21, Code of Federal Regulations (or any successor regulation) the following statement: ", "@parsable-cite": "cfr/21/201.57", "#text": "section 201.57", "@legal-doc": "regulation"}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(C)"}, "#text": "\n                ", "@id": "H4059CD46E51A4B8AA97411C80EE1E5E5", "@commented": "no"}], "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall apply with respect to approval under this subsection to the same extent and in the same manner as such provisions apply with respect to accelerated approval under ", "@entity-type": "act", "#text": "section 506(c)(2)(B)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:c/p:2/sp:B"}, {"#tail": ".", "@entity-type": "act", "#text": "section 506(c)(1)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:c/p:1"}], "#text": "The provisions of ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(2)"}, "header": {"#tail": "\n              ", "#text": "Promotional materials"}, "#text": "\n              ", "@id": "HBD23012930474F779FC2B3151C62791C", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", respectively, without such a limitation, the ", "@entity-type": "act", "#text": "section 351 of the Public Health Service Act", "@value": "Public Health Service Act/s:351"}, {"#tail": " may remove any labeling requirements or postmarketing conditions made applicable to the drug during the earlier approval process.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "If a drug is approved pursuant to this subsection to treat a limited population of patients and is subsequently approved or licensed under this section or ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(3)"}, "header": {"#tail": "\n              ", "#text": "Withdrawal of limited population approval requirements"}, "#text": "\n              ", "@id": "HD8698890DA47492DBAE78AFA2870A399"}, {"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", designation and treatment of a drug as a fast track product under ", "@entity-type": "act", "#text": "section 506(a)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:a"}, {"#tail": ", or accelerated approval of the drug under ", "@entity-type": "act", "#text": "section 506(b)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:b"}, {"#tail": ", in combination with approval of the drug for use in a limited population of patients under this subsection.", "@entity-type": "act", "#text": "section 506(c)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:c"}], "#text": "Nothing in this subsection shall be construed to prohibit designation and expedited review of a drug as a breakthrough therapy under "}, "enum": {"#tail": "\n              ", "#text": "(4)"}, "header": {"#tail": "\n              ", "#text": "Relation to other provisions"}, "#text": "\n              ", "@id": "H71DE12882BEC4CB49DD8D51696FD7354"}, {"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or ", "@entity-type": "act", "#text": "subsection (c)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:c"}, {"#tail": " (including the substantial evidence standard in ", "@entity-type": "act", "#text": "(d)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:d"}, {"#tail": "). ", "@entity-type": "act", "#text": "subsection (d)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:d"}, {"#tail": " and ", "@entity-type": "act", "#text": "Subsections (c)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:c"}, {"#tail": " and such standards of evidence apply to the review and approval of drugs under this subsection, including whether a drug is safe and effective. Nothing in this subsection shall be construed to limit the authority of the ", "@entity-type": "act", "#text": "(d)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:d"}, {"#tail": " to approve products pursuant to this Act and the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " as authorized prior to the date of enactment of this subsection.", "@entity-type": "act", "#text": "Public Health Service Act", "@value": "Public Health Service Act"}], "#text": "Nothing in this subsection shall be construed to alter the standards of evidence under ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(5)"}, "header": {"#tail": "\n              ", "#text": "Rule of construction"}, "#text": "\n              ", "@id": "H041CAE1F8B4B4456A64812759A0F0941"}, {"#tail": "\n          ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall have the authorities vested in the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " by this subsection beginning on the date of enactment of this subsection, irrespective of when and whether the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " promulgates final regulations to carry out this subsection.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "The "}, "enum": {"#tail": "\n              ", "#text": "(6)"}, "header": {"#tail": "\n              ", "#text": "Effective immediately"}, "#text": "\n              ", "@id": "HB3AC1941B1714721AB6DB2FFB968C8BB"}], "#text": "\n            ", "@id": "H201DCCF24EE943A4A9EE9805CE449F56", "@commented": "no"}, "@display-inline": "no-display-inline", "#text": "\n          ", "@id": "HF66A083968874E66BC7BDBEB62FF4DEE"}, "#text": "\n        ", "@id": "HFF70DAB6A6ED4F30A2D7F5B99B2A11BA"}, {"#tail": "\n      ", "text": {"#tail": "\n        ", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended\u2014", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 351(j) of the Public Health Service Act", "@value": "Public Health Service Act/s:351/ss:j"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "42 U.S.C. 262(j)", "@value": "usc/42/262/j"}, "@parsable-cite": "usc/42/262", "#text": "\n            ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Licensure of certain biological products"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n        ", "quote": [{"#tail": " and inserting ", "#text": "(j)"}, {"#tail": ";", "#text": "(j)(1)"}], "#text": "by striking "}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "HD7D95EAC6DBB45D9BDF62DD802CD85F1", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n        ", "quote": [{"#tail": " after ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ",", "@entity-type": "act", "#text": "505(x)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:x", "@proposed": "true"}, "#text": "\n              "}, {"#tail": "; and", "#text": "505(p),"}], "#text": "by inserting "}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "H7335DB92B4CD4741A4EB8F1EF80B364F", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n          ", "#text": "by adding at the end the following:"}, "enum": {"#tail": "\n          ", "#text": "(3)"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n          ", "#text": "."}, "#tail": "\n        ", "paragraph": {"#tail": "\n            ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " to the licensure of biological products under this section\u2014", "@entity-type": "act", "#text": "section 505(x) of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:x", "@proposed": "true"}, "#text": "In applying ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(2)"}, "#text": "\n              ", "@id": "HFF134B0702874AE3B0FEADD8083D9838", "subparagraph": [{"#tail": "\n              ", "text": {"#tail": "\n              ", "#text": "references to an antibacterial or antifungal drug that is intended to treat a serious or life-threatening disease or condition shall be construed to refer to biological products intended to treat a bacterial or fungal infection associated with a serious or life-threatening disease; and", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "@id": "H75697B89377E45E19787EFEC7114ACB2", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall be construed to refer to licensure of a biological product under subsection (a) of this section.", "@entity-type": "act", "#text": "section 505(c) of such Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:c"}, "#text": "references to approval of a drug under "}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "@id": "H991EAB9ABA52459981EBB4C78C56CBB9", "#text": "\n                "}]}, "@display-inline": "no-display-inline", "#text": "\n            ", "@id": "HA3A60261C55C469D8AF10076275CA27E"}, "#text": "\n          ", "@id": "H72E1E5676FC04ED986635C45A4994C16"}], "#text": "\n        ", "@id": "HAAB93BF856994C39A5CFC9A084CFB0B1"}, {"#tail": "\n    ", "text": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " is amended by inserting after ", "@entity-type": "act", "#text": "Title III of the Public Health Service Act", "@value": "Public Health Service Act/t:III"}, "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " the following:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 317T", "@value": "Public Health Service Act/s:317T"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "42 U.S.C. 247b\u201322", "@value": "usc/42/247b\u201322"}, "@parsable-cite": "usc/42/247b-22", "#text": "\n            ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n        ", "#text": "(c)"}, "header": {"#tail": "\n        ", "#text": "Monitoring"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n        ", "#text": "."}, "#tail": "\n      ", "section": {"#tail": "\n          ", "enum": {"#tail": "\n            ", "#text": "317U."}, "header": {"#tail": "\n            ", "#text": "Monitoring antibacterial and antifungal drug use and resistance"}, "subsection": [{"#tail": "\n            ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", acting through the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ", shall use the National Healthcare Safety Network or another appropriate monitoring system to monitor\u2014", "@entity-type": "federal-body", "#text": "Director of the Centers for Disease Control and Prevention", "@entity-id": "7523"}], "#text": "The ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(a)"}, "header": {"#tail": "\n              ", "#text": "Monitoring"}, "paragraph": [{"#tail": "\n              ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "; and", "@entity-type": "act", "#text": "section 505(x) of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:x", "@proposed": "true"}, "#text": "the use of antibacterial and antifungal drugs, including those receiving approval or licensure for a limited population pursuant to "}, "enum": {"#tail": "\n                ", "#text": "(1)"}, "@id": "HA22BC24585024B8C93C2AE77E1C15FB4", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n              ", "#text": "changes in bacterial and fungal resistance to drugs."}, "enum": {"#tail": "\n                ", "#text": "(2)"}, "@id": "H9029ACA5E2974CDCB15078452FCBA3EE", "#text": "\n                "}], "#text": "\n              ", "@id": "H1B716AE616FF49C386FFBA4B34CF7286"}, {"#tail": "\n          ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", acting through the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ", shall make the data derived from monitoring under this section publicly available for the purposes of\u2014", "@entity-type": "federal-body", "#text": "Director of the Centers for Disease Control and Prevention", "@entity-id": "7523"}], "#text": "The "}, "enum": {"#tail": "\n              ", "#text": "(b)"}, "header": {"#tail": "\n              ", "#text": "Public availability of data"}, "paragraph": [{"#tail": "\n              ", "text": {"#tail": "\n              ", "#text": "improving the monitoring of important trends in antibacterial and antifungal resistance; and"}, "enum": {"#tail": "\n                ", "#text": "(1)"}, "@id": "H2C9EF6282D034DFCB97E94156B169E74", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "section 505(x) of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:x", "@proposed": "true"}, "#text": "ensuring appropriate stewardship of antibacterial and antifungal drugs, including those receiving approval or licensure for a limited population pursuant to ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(2)"}, "@id": "H50C5153AE69A463ABCD051E36A1ACB43", "#text": "\n                "}], "#text": "\n              ", "@id": "H191DD5153E4A4CFD839ED293A15CE6EB"}], "#text": "\n            ", "@id": "H2DBC4188EEAF4D5C95DF58BADB8491E9"}, "@display-inline": "no-display-inline", "#text": "\n          ", "@id": "HF4A9C8CE94D44192BD8900E06BA9384A"}, "#text": "\n        ", "@id": "H95341D8CCC054822833D75E04C65693F"}], "#text": "\n      ", "@id": "H5498C318763C4FDCAAA72D0347A6A56E"}, {"#tail": "\n    ", "enum": {"#tail": "\n      ", "#text": "3."}, "header": {"#tail": "\n      ", "#text": "Susceptibility test interpretive criteria for microbial organisms"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n        ", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended to read as follows:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 511 of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:511"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "21 U.S.C. 360a", "@value": "usc/21/360a"}, "@parsable-cite": "usc/21/360a", "#text": "\n            ", "@legal-doc": "usc"}}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "In general"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n        ", "#text": "."}, "#tail": "\n      ", "section": {"#tail": "\n          ", "enum": {"#tail": "\n            ", "#text": "511."}, "header": {"#tail": "\n            ", "#text": "Susceptibility test interpretive criteria for microbial organisms"}, "subsection": [{"#tail": "\n            ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall identify upon approval and subsequently update susceptibility test interpretive criteria for antibacterial drugs (including biological products intended to treat a bacterial infection and other types of antimicrobial drugs, as deemed appropriate by the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": "), including qualified infectious disease products, by relying upon, to the extent available\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "The ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(a)"}, "header": {"#tail": "\n              ", "#text": "In general"}, "paragraph": [{"#tail": "\n              ", "text": {"#tail": "\n              ", "#text": "preclinical and clinical data, including pharmacokinetic, pharmacodynamic, and epidemiological data;"}, "enum": {"#tail": "\n                ", "#text": "(1)"}, "@id": "H9CE3783438DD49A5A84998A9D66228EA", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n              ", "#text": "Bayesian and pharmacometric statistical methodologies; and"}, "enum": {"#tail": "\n                ", "#text": "(2)"}, "@id": "HDB425A38608A47C1BB94109A107001F4", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " deems necessary.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "such other confirmatory evidence as the "}, "enum": {"#tail": "\n                ", "#text": "(3)"}, "@id": "H8DDD2B2A955A4C33991BCD76CAA2536E", "#text": "\n                "}], "#text": "\n              ", "@id": "H7EDED925B6874A6DB07F291E22B9CD59"}, {"#tail": "\n            ", "enum": {"#tail": "\n              ", "#text": "(b)"}, "header": {"#tail": "\n              ", "#text": "Responding to susceptibility test interpretive criteria identified or updated by private entities"}, "paragraph": [{"#tail": "\n              ", "@id": "HA8213E5DBAB64DD8AC8A37F603FA00DC", "enum": {"#tail": "\n                ", "#text": "(1)"}, "header": {"#tail": "\n                ", "#text": "In general"}, "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "Each quarter of each fiscal year, the "}, "#text": "\n                ", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n                ", "#text": "evaluate any appropriate new or updated susceptibility test interpretive criteria published by a nationally or internationally recognized standard development organization; and"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@id": "H4F1A0A93EE7143E5B4573E26B55D948F", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n                  ", "#text": "publish on the public Website of the Food and Drug Administration a notice\u2014"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n                  ", "#text": "adopting the new or updated interpretive criteria;"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "@id": "H1E9C3BDA08DF4439BF731C5D5CEA6039", "#text": "\n                    "}, {"#tail": "\n                  ", "text": {"#tail": "\n                  ", "#text": "declining to adopt the new or updated interpretive criteria and explaining the reason for such decision; or"}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "@id": "HB8CC378D44BF47C3820055135FAC38F0", "#text": "\n                    "}, {"#tail": "\n                ", "text": {"#tail": "\n                  ", "#text": "adopting one or more parts of the new or updated interpretive criteria, declining to adopt the remainder of such criteria, and explaining the reason for so declining."}, "enum": {"#tail": "\n                    ", "#text": "(iii)"}, "@id": "H59886C120A5849758D8C6CEF704B28CC", "#text": "\n                    "}], "#text": "\n                  ", "@id": "H414642BEDB7E49A883D45D7D8140A3F7"}]}, {"#tail": "\n              ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall compile the notices published under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " and publish such compilation in the Federal Register.", "@entity-type": "act", "#text": "paragraph (1)(B)", "@value": "Federal Food, Drug, and Cosmetic Act/s:511/ss:b/p:1/sp:B", "@proposed": "true"}], "#text": "Each year, the "}, "enum": {"#tail": "\n                ", "#text": "(2)"}, "header": {"#tail": "\n                ", "#text": "Annual compilation of notices"}, "#text": "\n                ", "@id": "HB67F65FE122F418A82665C58C4417E96"}, {"#tail": "\n              ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " may be recognized as a standard by the ", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Federal Food, Drug, and Cosmetic Act/s:511/ss:b/p:1", "@proposed": "true"}, {"#tail": " under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ".", "@entity-type": "act", "#text": "section 514(c)(1)", "@value": "Federal Food, Drug, and Cosmetic Act/s:514/ss:c/p:1"}], "#text": "Any susceptibility test interpretive criterion for which an approval is in effect under ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(3)"}, "header": {"#tail": "\n                ", "#text": "Relation to section 514(", "enum-in-header": {"#tail": ")", "#text": "c"}}, "#text": "\n                ", "@id": "H0D6DBEE65434409596E658B7C75C1498"}, {"#tail": "\n            ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Federal Food, Drug, and Cosmetic Act/s:511/ss:b/p:1", "@proposed": "true"}, "#text": "Nothing in this section prohibits the sponsor of a drug or device from seeking approval or clearance of the drug or device, or changes to the drug, the device, or its labeling, on the basis of susceptibility test interpretive criteria which differ from those adopted pursuant to "}, "enum": {"#tail": "\n                ", "#text": "(4)"}, "header": {"#tail": "\n                ", "#text": "Use of non-adopted criteria"}, "#text": "\n                ", "@id": "H8C9B4D4DA9CA4B44A573B0D09487AD94"}], "#text": "\n              ", "@id": "HF90A5A9199A247C5960CC5727D962CD5"}, {"#tail": "\n          ", "text": {"#tail": "\n              ", "#text": "In this section:"}, "enum": {"#tail": "\n              ", "#text": "(c)"}, "header": {"#tail": "\n              ", "#text": "Definitions"}, "paragraph": [{"#tail": "\n              ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "505E(d)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505E/ss:d"}, "term": {"#tail": " means a qualified infectious disease product designated under ", "#text": "qualified infectious disease product"}, "#text": "The term "}, "enum": {"#tail": "\n                ", "#text": "(1)"}, "#text": "\n                ", "@id": "H0460DFCC9D7A4669B2452CD434F441CD", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n              ", "term": {"#tail": " means one or more specific values which characterize the degree to which bacteria or other microbes are resistant to the drug (or drugs) tested, such as clinically susceptible, intermediate, or resistant.", "#text": "susceptibility test interpretive criteria"}, "#text": "The term ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(2)"}, "@id": "H11C96BE61161481183D378CF60EF53A4", "#text": "\n                "}], "#text": "\n              ", "@id": "H6796C111B31447D2AFF43F8DE7400E26"}], "#text": "\n            ", "@id": "HB372BAD007344198BD105764ECC0AD3A"}, "#text": "\n          ", "@id": "HBF84DA49E70A46219662CD674C3BE2D4"}, "#text": "\n        ", "@id": "HCED63DACFC4341F6A609ADBA31A9BF20"}, {"#tail": "\n      ", "text": {"#tail": "\n      ", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " relating to identification of clinically susceptible concentrations of antimicrobials) is repealed.", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "Section 1111 of the Food and Drug Administration Amendments Act of 2007", "@value": "Food and Drug Administration Amendments Act of 2007/s:1111"}, {"#tail": ";", "@entity-type": "uscode", "#text": "42 U.S.C. 247d\u20135a", "@value": "usc/42/247d\u20135a"}], "@entity-type": "law-citation", "#text": "\n            "}}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Conforming amendment"}, "#text": "\n        ", "@id": "H52CE128312614A9E8D34409CDDCDC283"}, {"#tail": "\n    ", "text": {"#tail": "\n      ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall submit to the ", "@entity-type": "federal-body", "#text": "Secretary of Health and Human Services", "@entity-id": "7500"}, {"#tail": " and the ", "@entity-type": "committee", "#text": "Committee on Energy and Commerce of the House of Representatives", "@entity-id": "HIF00"}, {"#tail": " a report on the progress made in implementing ", "@entity-type": "committee", "#text": "Committee on Health, Education, Labor, and Pensions of the Senate", "@entity-id": "SSHR00"}], "#text": "Not later than one year after the date of enactment of this Act, the ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ", as amended by this section.", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 511 of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:511", "@proposed": "true"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "21 U.S.C. 360a", "@value": "usc/21/360a", "@proposed": "true"}, "@parsable-cite": "usc/21/360a", "#text": "\n            ", "@legal-doc": "usc"}}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(c)"}, "header": {"#tail": "\n        ", "#text": "Report to Congress"}, "#text": "\n        ", "@id": "HDD045620DA5844D28FFC6571EF74B94F"}], "#text": "\n      ", "@id": "H4F0C70A5D35F4D7BB6DB1590DE05FDDA"}, {"#tail": "\n  ", "text": {"short-title": {"#tail": " (including the amendments made thereby) shall be construed to restrict, in any manner, the prescribing of antibiotics or other products by health care professionals, or to limit the practice of health care.", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n        ", "@entity-type": "act", "#text": "Antibiotic Development to Advance Patient Treatment Act of 2013", "@value": "Antibiotic Development to Advance Patient Treatment Act of 2013", "@proposed": "true"}, "#text": "\n          "}, "#tail": "\n    ", "#text": "Nothing in the ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "4."}, "header": {"#tail": "\n      ", "#text": "No effect on health care practice"}, "#text": "\n      ", "@id": "H78CD432938E345DBAA74C1BABBDC1CB5", "@commented": "no"}], "#text": "\n    ", "@id": "H944E9726E44E454FA7D41E0238D8F2B7"}, "metadata": {"#tail": "\n", "dublinCore": {"{http://purl.org/dc/elements/1.1/}date": {"#tail": "\n", "#text": "2013-12-12"}, "{http://purl.org/dc/elements/1.1/}format": {"#tail": "\n", "#text": "text/xml"}, "{http://purl.org/dc/elements/1.1/}language": {"#tail": "\n", "#text": "EN"}, "#tail": "\n", "{http://purl.org/dc/elements/1.1/}title": {"#tail": "\n", "#text": "113 HR 3742 IH: Antibiotic Development to Advance Patient Treatment Act of 2013"}, "{http://purl.org/dc/elements/1.1/}rights": {"#tail": "\n", "#text": "Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain."}, "{http://purl.org/dc/elements/1.1/}publisher": {"#tail": "\n", "#text": "U.S. House of Representatives"}, "#text": "\n"}, "#text": "\n"}}}